Kaitlyn D’Onofrio

DocwireNews

A recent study assessed the risk of disease recurrence and <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/the-effect-of-the-opioid-epidemic-on-cancer-survivors/">survival</a> in multiple myeloma patients, using a conditional survival approach.&ldquo;Unlike the traditional method of overall survival prediction in patients with cancer, conditional survival predicts the survival of patients dynamically throughout the course of disease, identifying how a prognosis evolves over time,&rdquo; the researchers explained.They identified 815 consecutive <a href="https://www.docwirenews.com/conference-coverage/2020-hopa-annual-conference/multiple-myeloma-patients/">multiple myeloma patients</a> using the German Study Group on Multiple Myeloma (Deutsche Studiengruppe Multiples Myelom; DSMM) incentive. More than 10 variables were assessed upon diagnosis and on numerous occasions during follow-up; these variables included patient- and multiple myeloma-specific measures. Disease- and host-related risks were used to calculate the odds of five-year survival.Median follow-up and overall survival were 10.3 years and 5.1 years, respectively. Five-year conditional survival probabilities significantly changed when using data collected at the initial diagnosis updated overtime versus using follow-up data. When analyzing multivariate Cox regression models, the hazard ratio (HR) for surviving 0 to 5 years was 1 for patients aged &lt;60 years. HRs for patients aged 60 to 69 years and &gt;70 years were 1.68 and 3.17, respectively. Factors associated with declining HRs for age were surviving five years, having advanced stages of disease (II/III), and having unfavorable cytogenetics; progressive disease significantly impacted HRs for survival at one year (1.85), three years (2.11), and five years (2.14).The study was published in <a href="https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.32978">Cancer</a>.&ldquo;To the authors&rsquo; knowledge, the current study is the first analysis of conditional survival in patients with multiple myeloma using both baseline and follow&#8208;up risk parameters, demonstrating that regular risk assessment throughout the course of disease and complete follow&#8208;up provide a more reliable conditional survival estimation than baseline assessment alone,&rdquo; the researchers summarized.

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Researchers Use Conditional Survival Approach to Assess Disease Recurrence Risk and Survival in Multiple Myeloma

Oncology

A recent study assessed the risk of disease recurrence and survival in multiple myeloma patients, using a conditional survival approach. ...

Researchers Use Conditional Survival Approach to Assess Disease Recurrence Risk and Survival in

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe